History
2025: Pharma Medisorb bought Kinetic Farm
The Perm pharmaceutical company Medisorb acquired an 80% stake in the Kinetic Farm Moscow research laboratory, which specializes in the development of drugs for the treatment of diabetes, cardiovascular diseases and oncology. The transfer of shares to the parent company Medisorb Group took place in mid-May 2025.
According to Kommersant, Kinetic Farm was founded by the former general director of Drug Technology Dmitry Shobolov, who retained a 16% stake in the company. Another 4% is owned by Tamare Balayants. The amount of the transaction was not disclosed.
Kinetic Farm is registered in SolnechnogorskMoscow Region and conducts activities in the field of scientific research and development in the field of natural and technical sciences. The company is the legal successor of Garmonics LLC, established in 2019 in Moscow.
Dmitry Shobolov graduated from the Faculty of Pharmacy of the Sechenov Moscow Medical Academy. In his work experience - work in Lek d companies. d., SmithKline Beecham, Zeneca, Biocad, Biotek, Domestic Medicines and the position of general director of Drug Technology from the Himrar group.
The general director of Medisorb, Yuri Foteev, explained that Kinetic Farm is developing drugs based on chemically synthesized molecules without restrictions on therapeutic areas. According to him, investments in a research laboratory are part of a long-term strategy for the development and production of high-quality domestic generics in socially significant areas of medicine.
The purpose of the deal is to strengthen the research and development potential of Medisorb, which will expand the development portfolio by 10 drugs annually. The focus of attention of the Perm pharmaceutical manufacturer is generics with an innovative component for the treatment of cardiovascular diseases, diabetes and oncology.
Foteev stressed that the Perm holding plans to invest in the development of the scientific and technical base of the acquired asset. This will strengthen one of the key areas of work - research and design work to develop not just copies of drugs, but new drugs with an innovative component.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |